Related Experiment Video
Updated: May 15, 2025
09:10
Synthesis of Indoxyl-glycosides for Detection of Glycosidase Activities
Published on: May 27, 2015
6.6K
Metolazone and Azosemide, Clinically Utilized Diuretics, Exhibit Inhibitory Activity for Glyoxalase I
Masahiro Watanabe1, Takao Toyomura1, Hidenori Wake2
1Department of Pharmacology, School of Pharmacy, Shujitsu University, Okayama, Japan.
Biotechnology and Applied Biochemistry
|April 9, 2025
Summary
Certain diuretics, like metolazone and azosemide, inhibit glyoxalase I (GLO1), an enzyme that clears methylglyoxal (MGO). This inhibition can lead to MGO-derived advanced glycation endproducts (AGEs) accumulation, potentially impacting cell health.
Area of Science:
- Biochemistry
- Pharmacology
- Cell Biology
Background:
- Methylglyoxal (MGO) is a cytotoxic byproduct of glycolysis that forms advanced glycation endproducts (AGEs).
- Glyoxalase I (GLO1) is crucial for MGO detoxification, and its inhibition can lead to MGO accumulation.
- Quinetazone, a diuretic, was previously found to inhibit GLO1 activity.
Purpose of the Study:
- To investigate whether structurally similar diuretics to quinetazone also inhibit GLO1 activity.
- To determine the effects of GLO1-inhibiting diuretics on cell proliferation and MGO-derived AGEs accumulation.
Main Methods:
- Spectrophotometric determination of diuretic inhibitory activity against recombinant GLO1.
- MTT assay to evaluate cell proliferation.
- Western blotting to assess MGO-derived AGEs accumulation.
Main Results:
- Metolazone and azosemide significantly inhibited GLO1 activity (97% at 100 µM).
- Minimal inhibitory structures were identified as quinazolinone (metolazone) and phenyltetrazole (azosemide).
- These diuretics reduced cell proliferation and increased MGO-derived AGEs in HK-2 and EA.hy926 cells.
Conclusions:
- Metolazone and azosemide exhibit inhibitory effects on GLO1.
- Clinical use of these diuretics, especially at high or prolonged dosages, may contribute to pathogenesis via GLO1 inhibition and subsequent MGO/AGE accumulation.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
126
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
126
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
01:23Dipeptidyl Peptidase 4 Inhibitors
139
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
139
01:17Oral Hypoglycemic Agents: Sulfonylureas
165
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
165
01:06Oral Hypoglycemic Agents: Glinides
112
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
112
02:44Oxidation of Alkenes: Syn Dihydroxylation with Osmium Tetraoxide
9.7K
Alkenes are converted to 1,2-diols or glycols through a process called dihydroxylation. It involves the addition of two hydroxyl groups across the double bond with two different stereochemical approaches, namely anti and syn. Dihydroxylation using osmium tetroxide progresses with syn stereochemistry.
9.7K